This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
REVIEW UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Video Lectures
South-Central Section of the American Urological Association SCS AUA 2024
South-Central Section of the American Urological Association SCS AUA 2024 VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Yair Lotan
Details
Yair Lotan joins Zachary Klaassen to discuss the 36-month follow-up data of nadofaragene firadenovec for BCG-unresponsive bladder cancer. The phase 3 trial evaluates the long-term efficacy and safety of nadofaragene, an intravesical adenovirus vector administered every three months, in patients with carcinoma in situ and papillary disease. While initial response rates are promising, the discussion...
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah
Details
Ali Nasrallah discusses the BRAVO study (Bladder Cancer Recurrence Analysis in Veterans and Outcomes). The study examines the real-world impact of blue light cystoscopy versus white light cystoscopy in non-muscle invasive bladder cancer patients within the VA healthcare system. Using data from 1997 to 2021, the research demonstrates significantly reduced recurrence rates at three years with blue l...
Challenges in Transitioning Men from Active Surveillance to Watchful Waiting - Lisa Lowenstein
Details
Zachary Klaassen speaks with Lisa Lowenstein about transitioning men from active surveillance to watchful waiting in prostate cancer management. Dr. Lowenstein shares insights from her research on patient and clinician perspectives, highlighting the challenges of convincing men to reduce their monitoring intensity. She describes developing a shared decision-making intervention to help guide these...
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free